Suggestive Linkage of the Child Behavior Checklist Juvenile Bipolar Disorder Phenotype to 1p21, 6p21, and 8q21

 This article was reviewed under and accepted by Ad Hoc Editor James F. Leckman, M.D..

 This work was supported by R01HD37694 to Dr. Faraone and K08MH66072 to Dr. Doyle. Portions of this work were presented at the MGH-Ryan Licht Sang Pediatric Bipolar Disorder Foundation Conference, March 27, 2009, Cambridge, MA.

 Disclosure: Dr. Doyle has received research funding from the National Institute of Mental Health, Harvard Medical School, and the Stanley Foundation. She received consulting fees from Pfizer Inc in 2007 and speaker's fees from Reed Education in 2008. Dr. Biederman currently receives research support from the following sources: Alza, AstraZeneca, Bristol Myers Squibb, Eli Lilly and Co., Janssen Pharmaceuticals Inc., McNeil, Merck, Organon, Otsuka, Shire, National Institute of Mental Health (NIMH), and the National Institute of Child Health and Human Development (NICHD). In 2009, Dr. Biederman received a speaker's fee from the following sources: Fundacion Areces, Medice Pharmaceuticals, and the Spanish Child Psychiatry Association. In previous years, Dr. Biederman received research support, consultation fees, or speaker's fees for/from the following additional sources: Abbott, AstraZeneca, Celltech, Cephalon, Eli Lilly and Co., Esai, Forest, Glaxo, Gliatech, Janssen, McNeil, the National Alliance for Research on Schizophrenia and Depression (NARSAD), National Institute on Drug Abuse (NIDA), New River, Novartis, Noven, Neurosearch, Pfizer, Pharmacia, The Prechter Foundation, Shire, The Stanley Foundation, UCB Pharma, Inc., and Wyeth. Dr. Faraone, in the past year, has received consulting fees and has been on Advisory Boards for Eli Lilly and Shire and has received research support from Eli Lilly, Pfizer, Shire, and the National Institutes of Health. In previous years, he has received consulting fees or has been on Advisory Boards or has been a speaker for the following sources: Shire, McNeil, Janssen, Novartis, Pfizer, and Eli Lilly. In previous years he has received research support from Eli Lilly, Shire, Pfizer, and the National Institutes of Health. Drs. Ferreira and Smoller, and Ms Wong report no biomedical financial interests or potential conflicts of interest.

 This article is discussed in an editorial by Dr. Robert Althoff on page 302.

PII: S0890-8567(10)00084-5

doi: 10.1016/j.jaac.2010.01.008

© 2010 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.